Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia-Reference-Cited by-同舟云学术

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

Published:2013-02-28 Issue:4 Volume:90 Page:345-348
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Voso Maria Teresa¹,Breccia Massimo²,Lunghi Monia³,Poloni Antonella⁴,Niscola Pasquale⁵,Finelli Carlo⁶,Bari Alessia⁷,Musto Pellegrino⁸,Zambello Renato⁹,Fianchi Luana¹,Alimena Giuliana²,Leone Giuseppe¹

Affiliation:

1. Department of Hematology; Universita' Cattolica S. Cuore; Rome; Italy

2. Department of Hematology; Università La Sapienza; Rome; Italy

3. Department of Hematology; Università del Piemonte Orientale Amedeo Avogadro; Novara; Italy

4. Department of Hematology; Università Politecnica delle Marche; Ancona; Italy

5. Department of Hematology; Ospedale S. Eugenio; Roma; Italy

6. Department of Hematology; Universita' di Bologna; Bologna; Italy

7. Department of Hematology; Universita' di Modena and Reggio Emilia; Modena; Italy

8. Unità di Ematologia e Trapianto di Cellule Staminali; IRCCS; Centro di Riferimento Oncologico della Basilicata; Rionero in Vulture; Italy

9. Department of Clinical and Experimental Medicine; University of Padova; Padova; Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12079/fullpdf

Reference16 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes;Seymour;Crit Rev Oncol Hematol,2010

3. Comorbidities influence prognosis in MDS high-risk patients treated with 5-azacitidine;Sanna;Haematologica,2011

4. Vidaza Summary of Product Characteristics http://www.medicines.org.uk/EMC/medicine/21508/SPC/Vidaza%2025%20mg%20ml%20powder%20for%20suspension%20for%20injection/

5. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes;Silverman;Cancer,2011

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world study of the use of azacitidine in myelodysplasia in Australia;eJHaem;2024-05-17

2. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms;Clinical Hematology International;2022-12-27

3. DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES;Mediterranean Journal of Hematology and Infectious Diseases;2022-04-28

4. Oral hypomethylating agents: beyond convenience in MDS;Hematology;2021-12-10

5. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?;Future Oncology;2021-12